Drug Trial Radar · NCT05932472
Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial
Last checked: Nov 20, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32,706
Planned (sponsor's estimate)
Start
Jan 15, 2024
Primary completion
Jan 15, 2027
Study completion Feb 15, 2027
Sponsor
- Lead sponsor
- Tor Biering-SørensenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Wide variability in the antiplatelet effects of aspirin may lead to recurrent thromboembolic events. Several pilot studies have suggested potential benefits of taking aspirin at bedtime rather than in the morning. The primary objective of this study is to examine whether aspirin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking aspirin.
Conditions
- Atherosclerosis
- Cardiovascular Diseases
- Drug Effect
Interventions
AspirinDrug
Aspirin at currently prescribed dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of hospitalization for myocardial infarction, hospitalization for stroke, coronary revascularization, or cardiovascular deathTime frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte
Hellerup, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.